AVIR Stock Summary and Trading Ideas (Atea Pharmaceuticals | NASDAQ:AVIR)

Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).

Atea Pharmaceuticals trades on the NASDAQ stock market under the symbol AVIR.

As of December 23, 2025, AVIR stock price climbed to $3.43 with 535,647 million shares trading.

AVIR has a beta of 0.35, meaning it tends to be less sensitive to market movements. AVIR has a correlation of 0.02 to the broad based SPY ETF.

AVIR has a market cap of $267.97 million. This is considered a Small Cap stock.

In the last 3 years, AVIR traded as high as $5.19 and as low as $2.46.

The top ETF exchange traded funds that AVIR belongs to (by Net Assets): VTI, IWM, VXF, IWN, IBB.

AVIR has underperformed the market in the last year with a return of +7.5%, while SPY returned +17.6%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in AVIR shares. However, AVIR has outperformed the market in the last 3 month and 2 week periods, returning +17.1% and +7.2%, while SPY returned +3.5% and +0.9%, respectively. This indicates AVIR has been having a stronger performance recently.

AVIR support price is $3.11 and resistance is $3.23 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AVIR shares will trade within this expected range on the day.